Savara Inc Unamortized Debt Issuance Expense
Savara Inc (SVRA) had Unamortized Debt Issuance Expense of $161.00 thousand as of 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:UnamortizedDebtIssuanceExpense · last filed 2020-11-05
- 2020-09-30: Unamortized Debt Issuance Expense $161.00K.
- 2020-06-30: Unamortized Debt Issuance Expense $173.00K.
- 2020-03-31: Unamortized Debt Issuance Expense $189.00K.
- 2019-12-31: Unamortized Debt Issuance Expense $182.00K.
| Period end | Unamortized Debt Issuance Expense |
|---|---|
| 2020-09-30 | $161.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $173.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $189.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $182.00K 10-K · filed 2020-03-12 |
| 2019-09-30 | $202.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $221.00K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $243.00K 10-Q · filed 2019-05-09 |
| 2018-12-31 | $268.00K 10-K · filed 2019-03-13 |
| 2018-09-30 | $54.00K 10-Q · filed 2018-11-07 |
| 2018-06-30 | $67.00K 10-Q · filed 2018-08-09 |
| 2018-03-31 | $73.00K 10-Q · filed 2018-05-09 |
| 2017-12-31 | $83.00K 10-K · filed 2018-03-14 |
| 2017-09-30 | $91.00K 10-Q · filed 2017-11-08 |
| 2017-06-30 | $99.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $145.00K 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |